Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label active-controlled study of SHR-4597 inhalant in adults with asthma
CTR20251590Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4597 in asthma, sponsored by Hengrui Therapeutics. Started May 2025; status: active.
02
Drugs
SHR-4597
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20251590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251590.